What should I do if I become drug-resistant after taking Enasidenib?

Enasidenib (Enasidenib) is an oral drug that belongs to the class of IDH2 inhibitors. Its mechanism of action is by inhibiting the activity of isomerized dioxyacid dehydrogenase 2 (IDH2), thereby blocking abnormal metabolic pathways in leukemia cells. If a patient develops resistance to ensidipine after taking it, they should first consult a doctor. Since everyone's physique is different and their resistance to drugs is also different, patients cannot adjust the drug dosage by themselves. Your doctor will evaluate your current acute myeloid leukemia condition and develop a new treatment plan.

Your doctor may consider adjusting your ensidipine dose to increase its effectiveness. If resistance is evident, your doctor may recommend trying other treatments, such as chemotherapy, targeted therapy, or immunotherapy. Selecting an alternative treatment option that is appropriate for your patient will depend on your condition and your doctor's professional judgment. If applicable, doctors can also discuss with patients the opportunity to participate in relevant clinical trials, which may provide new treatments or drugs that may be a promising option for patients with high drug resistance.

Ensiidi plain investigational medicine is not currently on the market in the country, nor is it covered by medical insurance. The price of ensidipine plain medicine when it is launched overseas is very high, and the price of each box may be around 30,000 yuan (the price may fluctuate due to the exchange rate). Currently, there are cheaper generic encidipine drugs produced by other pharmaceutical companies overseas. For example, the price of Specification50mg*60 tablets produced by a Bangladesh pharmaceutical factory may be around 4,000 yuan per box (the price may fluctuate due to exchange rates). Its drug ingredients are basically the same as those of the original encidipine generic drug.